Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics - PubMed
5 hours ago
- #JAK-STAT pathway
- #alopecia areata
- #atopic dermatitis
- Alopecia areata (AA) and atopic dermatitis (AD) share significant immunological overlap despite historical classification as distinct Th1 and Th2 conditions.
- Both diseases exhibit multi-axis cytokine dysregulation involving the JAK-STAT pathway and regulatory T cell dysfunction.
- Epidemiological data shows up to 40% of AA patients have atopic comorbidities, and they share genetic susceptibility loci like IL-13 and HLA.
- Key shared biomarkers include elevated IL-4, IL-13, IgE, and dysregulated interferon-gamma and IL-15 signaling.
- JAK inhibitors (e.g., baricitinib, ritlecitinib) have demonstrated efficacy in treating both AA and AD by interrupting central cytokine signaling.
- Dupilumab, approved for AD, benefits a subset of AA patients with concurrent atopic disease, indicating pathophysiologic heterogeneity.
- Emerging investigational therapies target pathways like OX40/OX40 ligand, IL-2 receptor, IL-7 receptor, and tri-specific cytokine inhibitors to restore immune homeostasis.